Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | YARS1 | P54577 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11431737 | 1.00 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9327248 | 1.00 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL14288987 | 0.90 | MAPT (0.44) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL8597022 | 0.90 | ATM (0.42) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL7828421 | 0.90 | ATM (0.42) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL3731768 | 0.89 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL3731770 | 0.89 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL28435235 | 0.89 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL27461765 | 0.89 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL8113253 | 0.89 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119330894-A | Method for synthesizing HO-EPCP by catalyzing DMAP | 山东鑫泉医药有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-118930559-A | Cefoperazone Process for the preparation of ketones | 苏州东瑞制药有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-118930559-B | Cefoperazone Process for the preparation of ketones | 苏州东瑞制药有限公司 | 2025-10-14 | — | — | CN | disclosed |
| CN-119330894-A | Method for synthesizing HO-EPCP by catalyzing DMAP | 山东鑫泉医药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119330894-A | Method for synthesizing HO-EPCP by catalyzing DMAP | 山东鑫泉医药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119330894-A | Method for synthesizing HO-EPCP by catalyzing DMAP | 山东鑫泉医药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-118930559-A | Cefoperazone Process for the preparation of ketones | 苏州东瑞制药有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118930559-A | Cefoperazone Process for the preparation of ketones | 苏州东瑞制药有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-117105955-A | Process for preparing intermediate compound of cefoperazone and cefoperazone or its salt | 国药集团威奇达药业有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117105957-A | Preparation method of cefoperazone acid | 国药集团威奇达药业有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117003768-A | Preparation method of cefoperazone impurity A | 国药集团威奇达药业有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-115463096-A | Cephalosporin synergistic sustained-release preparation and preparation method thereof | 安徽中龙神力生物科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-216459439-U | Centrifuge is used in preparation of injection type cephalosporin product | 永丰尚峰医药有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | GLADIUS PHARMACEUTICALS INC (CA) | 2019-04-04 | — | — | US | disclosed |
| CN-103980210-A | Method for preparing D(-)-alpha-(4-ethyl-2,3-dioxopiperazine-1-formamido) p-hydoxyphenylacetic acid | SHANDONG IFT SCIENCE & TECHNOLOGY CO LTD | 2014-08-13 | — | — | CN | disclosed |
| CN-103980210-A | Method for preparing D(-)-alpha-(4-ethyl-2,3-dioxopiperazine-1-formamido) p-hydoxyphenylacetic acid | SHANDONG IFT SCIENCE & TECHNOLOGY CO LTD | 2014-08-13 | — | — | CN | disclosed |
| CN-103641847-A | Preparation method of cefoperazone acid | SHANDONG XINQUAN PHARMACEUTICAL CO LTD | 2014-03-19 | — | — | CN | disclosed |
| EP-0550775-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-07-14 | — | — | EP | disclosed |
| EP-0492277-A2 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | PGLS, GNE, COMT | MAPT 2491/4885PDE3A 1670/4885SLC22A6 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.